Tenecteplase Thrombolysis for Stroke up to 24 Hours After Onset With Perfusion Imaging Selection: The CHABLIS-T II Randomized Clinical Trial

医学 溶栓 特奈特普酶 改良兰金量表 冲程(发动机) 灌注扫描 随机对照试验 闭塞 心脏病学 内科学 麻醉 灌注 缺血 心肌梗塞 缺血性中风 机械工程 工程类
作者
Xin Cheng,Lan Hong,Longting Lin,Leonid P. Churilov,Yifeng Ling,Nan Yang,Jianliang Fu,Guozhi Lu,Yunhua Yue,Jin Zhang,Feng Wang,Ziran Wang,Yanxin Zhao,Xiaoyu Zhou,Zhaolong Peng,Danhong Wu,Liandong Zhao,Qijin Zhai,Xiaofei Yu,Qi Fang
出处
期刊:Stroke [Lippincott Williams & Wilkins]
卷期号:56 (2): 344-354 被引量:55
标识
DOI:10.1161/strokeaha.124.048375
摘要

BACKGROUND: Whether it is effective and safe to extend the time window of intravenous thrombolysis up to 24 hours after the last known well is unknown. We aimed to determine the efficacy and safety of tenecteplase in Chinese patients with acute ischemic stroke due to large/medium vessel occlusion within an extended time window. METHODS: Patients with ischemic stroke presenting 4.5 to 24 hours from the last known well, with a favorable penumbral profile and an associated large/medium vessel occlusion, were randomized 1:1 to either 0.25 mg/kg tenecteplase or the best medical treatment. A favorable penumbral profile was defined as a hypoperfusion lesion volume to infarct core volume ratio >1.2, with an absolute volume difference >10 mL, and an ischemic core volume <70 mL. The primary outcome was the achievement of major reperfusion without symptomatic intracranial hemorrhage within 24 to 48 hours post-randomization. Major reperfusion was defined as the restoration of blood flow of >50% of the involved ischemic territory. Secondary outcomes included recanalization, infarct growth, major neurological improvements, change in the National Institutes of Health Stroke Scale score, hemorrhagic transformation within 24 to 48 hours, systemic bleeding at discharge, and modified Rankin Scale (score 0–1, score 0–2, score 5–6, and modified Rankin Scale distribution) at 90 days. The comparison of the primary outcome between groups was conducted using modified Poisson regression with a log-link function and robust error variance, adjusted for time from the last known well to randomization, the site of vessel occlusion, and planned endovascular treatment. RESULTS: Among 224 enrolled patients, 111 were assigned to receive tenecteplase and 113 to receive the best medical treatment (including 23% [n=26] of participants who received intravenous tissue-type plasminogen activator). The mean (SD) age of the tenecteplase group and the best medical treatment group was 64.2 (10.4) and 63.6 (11.0) years old, with 72.1% (n=80) and 70.8% (n=80) male enrolled, respectively. A proportion of 54.9% (n=123) of patients were transferred to the catheter room for preplanned endovascular treatment. The primary outcome occurred in 33.3% (n=37) of the tenecteplase group versus 10.8% (n=12) in the best medical treatment group (adjusted relative risk, 3.0 [95% CI, 1.6–5.7]; P =0.001). Tenecteplase significantly increased the recanalization rate compared with the best medical treatment (35.8% [n=39] versus 14.3% [n=16], adjusted relative risk, 2.5 [95% CI, 1.4–4.4]; P =0.002). There were no significant differences in clinical efficacy outcomes or rates of hemorrhagic transformation between the groups. CONCLUSIONS: Administered at a dose of 0.25 mg/kg intravenously, tenecteplase increased reperfusion without symptomatic intracranial hemorrhage in patients with ischemic stroke selected by imaging in late-time window treatment but did not change clinical outcomes at 90 days. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04516993.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
打打的应助被无敌小宝贝采纳,获得10
1秒前
Polya完成签到 ,获得积分10
1秒前
2秒前
2秒前
单薄幻梦发布了新的文献求助10
2秒前
奈特奶糖发布了新的文献求助10
2秒前
3秒前
陶醉采白发布了新的文献求助10
3秒前
3秒前
4秒前
Trueman完成签到,获得积分10
5秒前
乔一发布了新的文献求助10
5秒前
6秒前
li发布了新的文献求助10
6秒前
QIAO发布了新的文献求助10
7秒前
蒲勇兵完成签到 ,获得积分10
10秒前
maT关闭了maT的文献求助
10秒前
szxa发布了新的文献求助10
10秒前
10秒前
梅梅完成签到,获得积分10
11秒前
11秒前
科研通AI6.2的应助被szztty采纳,获得10
12秒前
科研通AI6.3的应助被瞿qks采纳,获得10
12秒前
爱笑凤凰发布了新的文献求助20
12秒前
12秒前
CarryLJR的应助被玩家666采纳,获得10
14秒前
佳佳完成签到 ,获得积分10
14秒前
本微尘发布了新的文献求助10
15秒前
15秒前
火火完成签到,获得积分10
17秒前
18秒前
科研通AI2S的应助被纯真大象采纳,获得10
18秒前
淡定发布了新的文献求助10
18秒前
19秒前
晚晚完成签到 ,获得积分10
19秒前
19秒前
orixero的应助被zzzmh采纳,获得10
19秒前
20秒前
斯文败类的应助被神勇的筝采纳,获得10
21秒前
东京蔡徐坤完成签到,获得积分20
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178960
求助须知:如何正确求助?哪些是违规求助? 9569638
关于积分的说明 21805682
捐赠科研通 7774071
什么是DOI,文献DOI怎么找? 3432955
关于科研通互助平台的介绍 2556897
邀请新用户注册赠送积分活动 2478640